Adaptive Biotechnologies Azioni (NASDAQ: ADPT)

Adaptive Biotechnologies

ADAPTIVE BIOTECHNOLOGIES

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Adeptus Health

Stuttgart,,Germany,-,03-11-2021:,Person,Holding,Cellphone,With,Company,Logo

Equities

News

Markets

ETFs

ADPT

ARKQ

NRIX

NVDA

PATH

Nuovi acquisti per il fondo guidato dalla celebre investitrice, focus su un settore chiave. Ribilanciamento in corso nel portafoglio.

Cathie Wood non si ferma più: Ark Invest compra ancora questi titoli

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

Press Releases

General

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Earnings

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Health Care

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

GRND

TRUP

VCSA

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Adaptive Biotechnologies

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO